Ascelia Pharma (ACE) Stock Overview
A biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
ACE Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Ascelia Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.59 |
| 52 Week High | SEK 5.13 |
| 52 Week Low | SEK 0.46 |
| Beta | 0.83 |
| 1 Month Change | 15.69% |
| 3 Month Change | -79.55% |
| 1 Year Change | -87.58% |
| 3 Year Change | -85.77% |
| 5 Year Change | -97.85% |
| Change since IPO | -97.63% |
Recent News & Updates
ACE: FDA Type A Meeting Will Shape Long-Term Upside Potential
Analysts have trimmed their price target on Ascelia Pharma from SEK 2.87 to SEK 2.40, reflecting updated assumptions around discount rates, profit expectations and future P/E levels. What's in the News for Ascelia Pharma Ascelia Pharma received a Complete Response Letter from the U.S. FDA on the New Drug Application for Orviglance, with the agency stating it is currently unable to approve the filing in its present form and requesting additional clinical data and product documentation.ACE: Future FDA Resolution Will Support Long-Term Prospects Despite Current Concerns
Ascelia Pharma's analyst price target has been revised to SEK 2.87 from SEK 4.28, with analysts citing updated assumptions on fair value, revenue growth and profit margins as the main drivers of the change. What’s in the News for Ascelia Pharma Ascelia Pharma received a Complete Response Letter from the U.S. FDA on its New Drug Application for Orviglance.
ACE: FDA Type A Meeting Will Drive Reassessment Of Long-Term Upside
Analysts have cut their Ascelia Pharma price target to SEK 3.70 from SEK 8.50, citing updated assumptions around revenue growth, profit margins and a lower future P/E multiple that together point to a more cautious valuation framework. What’s in the News for Ascelia Pharma Ascelia Pharma received a Complete Response Letter (CRL) from the U.S. FDA on its New Drug Application for Orviglance, with the agency requesting additional clinical data and product documentation.Recent updates
ACE: FDA Type A Meeting Will Shape Long-Term Upside Potential
Analysts have trimmed their price target on Ascelia Pharma from SEK 2.87 to SEK 2.40, reflecting updated assumptions around discount rates, profit expectations and future P/E levels. What's in the News for Ascelia Pharma Ascelia Pharma received a Complete Response Letter from the U.S. FDA on the New Drug Application for Orviglance, with the agency stating it is currently unable to approve the filing in its present form and requesting additional clinical data and product documentation.ACE: Future FDA Resolution Will Support Long-Term Prospects Despite Current Concerns
Ascelia Pharma's analyst price target has been revised to SEK 2.87 from SEK 4.28, with analysts citing updated assumptions on fair value, revenue growth and profit margins as the main drivers of the change. What’s in the News for Ascelia Pharma Ascelia Pharma received a Complete Response Letter from the U.S. FDA on its New Drug Application for Orviglance.ACE: FDA Type A Meeting Will Drive Reassessment Of Long-Term Upside
Analysts have cut their Ascelia Pharma price target to SEK 3.70 from SEK 8.50, citing updated assumptions around revenue growth, profit margins and a lower future P/E multiple that together point to a more cautious valuation framework. What’s in the News for Ascelia Pharma Ascelia Pharma received a Complete Response Letter (CRL) from the U.S. FDA on its New Drug Application for Orviglance, with the agency requesting additional clinical data and product documentation.ACE: Rising Long-Term Prospects Will Outweigh Present Going Concern Risk
Analysts have revised their price target on Ascelia Pharma to SEK4.28 from SEK6.32, reflecting updated assumptions on the discount rate, revenue growth outlook, profit margin expectations, and future P/E multiples. What's in the News for Ascelia Pharma Ascelia Pharma scheduled an Analyst and Investor Day, described as "Ascelia Pharma AB (publ) Analyst/Investor Day," giving the market a dedicated forum to hear directly from management and review the company story.Renal Imaging Opportunity Will Support Future Rare Oncology Expansion Narrative
Catalysts About Ascelia Pharma Ascelia Pharma develops and commercializes drugs in rare oncology, with a focus on liver imaging and oral chemotherapy. What are the underlying business or industry changes driving this perspective?
Severe Regulatory And Funding Risks Around Cancer Imaging Will Eventually Reward Patient Safety Focus
Catalysts About Ascelia Pharma Ascelia Pharma develops and commercializes specialty drugs for rare cancer related conditions, focused on diagnostic imaging and oral oncology treatments. What are the underlying business or industry changes driving this perspective?Manganese Contrast Agent Safety Tailwinds Will Support Long Term Upside Potential
Catalysts About Ascelia Pharma Ascelia Pharma develops and commercializes specialty drugs for rare, cancer related conditions. What are the underlying business or industry changes driving this perspective?We're Hopeful That Ascelia Pharma (STO:ACE) Will Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Is Ascelia Pharma (STO:ACE) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Is Ascelia Pharma (STO:ACE) Using Debt In A Risky Way?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Is Ascelia Pharma (STO:ACE) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Health Check: How Prudently Does Ascelia Pharma (STO:ACE) Use Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Is Ascelia Pharma (STO:ACE) Using Debt In A Risky Way?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Is Ascelia Pharma (STO:ACE) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Ascelia Pharma (STO:ACE) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...We Think Ascelia Pharma (STO:ACE) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Shareholder Returns
| ACE | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 1.7% | 3.0% | -1.1% |
| 1Y | -87.6% | 26.2% | 10.6% |
Return vs Industry: ACE underperformed the Swedish Biotechs industry which returned 26.2% over the past year.
Return vs Market: ACE underperformed the Swedish Market which returned 10.6% over the past year.
Price Volatility
| ACE volatility | |
|---|---|
| ACE Average Weekly Movement | 24.3% |
| Biotechs Industry Average Movement | 9.0% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.1% |
| 10% least volatile stocks in SE Market | 3.1% |
Stable Share Price: ACE's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: ACE's weekly volatility has increased from 14% to 24% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 10 | Magnus Corfitzen | www.ascelia.com |
Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment of gastric cancer. The company has a collaboration agreement with the Taiho Oncology Inc. The company was incorporated in 1999 and is headquartered in Malmö, Sweden.
Ascelia Pharma AB (publ) Fundamentals Summary
| ACE fundamental statistics | |
|---|---|
| Market cap | SEK 73.44m |
| Earnings (TTM) | -SEK 70.90m |
| Revenue (TTM) | n/a |
Is ACE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACE income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 70.90m |
| Earnings | -SEK 70.90m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Nov 05, 2026
| Earnings per share (EPS) | -0.53 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ACE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/20 22:18 |
| End of Day Share Price | 2026/08/20 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ascelia Pharma AB (publ) is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier Sponsored |
| Lars Hevreng | Danske Bank |
| Maria Karlsson Osipova | DNB Carnegie Commissioned Research |